Lirentelimab Market Size, Forecast, and Emerging Insight - 2032

Lirentelimab Market Size, Forecast, and Emerging Insight − 2032

“Lirentelimab Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about Lirentelimab for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the Lirentelimab for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the Lirentelimab for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Lirentelimab market forecast analysis for CSU in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary

Lirentelimab (AK002, antolimab) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (Siglec-8). Siglec-8 is an inhibitory receptor in eosinophils and mast cells, with low-level basophil expression. Thus, lirentelimab depletes eosinophils via antibody-dependent natural killer cell-mediated cytotoxicity and inhibition of FceRI-mediated histamine release (Altrichter et al., 2022).

AK002 has demonstrated activity in animal disease models of eosinophilic and mast cell-driven diseases. The company has completed a Phase II study to treat chronic urticaria and another Phase II is ongoing in CSU patients.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Lirentelimab description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).

Elaborated details on Lirentelimab regulatory milestones and other development activities have been provided in this report.

The report also highlights the Lirentelimab research and development activities in CSU across the United States, Europe, and Japan.

The report also covers the patents information with expiry timeline around Lirentelimab.

The report contains forecasted sales of Lirentelimab for CSU till 2032.

Comprehensive coverage of the late-stage emerging therapies for CSU.

The report also features the SWOT analysis with analyst views for Lirentelimab in CSU.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Lirentelimab Analytical Perspective by DelveInsight

In-depth Lirentelimab Market Assessment

This report provides a detailed market assessment of Lirentelimab for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

Lirentelimab Clinical Assessment

The report provides the clinical trials information of Lirentelimab for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Lirentelimab dominance.

Other emerging products for CSU are expected to give tough market competition to Lirentelimab and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Lirentelimab in CSU.

Our in-depth analysis of the forecasted sales data of Lirentelimab from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lirentelimab in CSU.

Key Questions

What is the product type, route of administration and mechanism of action of Lirentelimab?

What is the clinical trial status of the study related to Lirentelimab in Chronic Spontaneous Urticaria (CSU) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Lirentelimab development?

What are the key designations that have been granted to Lirentelimab for CSU?

What is the forecasted market scenario of Lirentelimab for CSU?

What are the forecasted sales of Lirentelimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

What are the other emerging products available and how are these giving competition to Lirentelimab for CSU?

Which are the late-stage emerging therapies under development for the treatment of CSU?